The OCMX™ is pleased to announce the listing of Neurocarrus to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

MONTEREY, CA, June 07, 2019 /24-7PressRelease/ — Drug development leading to clinical trials of new human pain therapeutic.

Treating Pain, Without Addiction

Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet need for a product that can safely and specifically regulate peripheral sensory neurons. N-001 was engineered for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute pain, such as pain following surgery. N-001 is a leading technology in the fight against the opioid crisis, which claims the lives of tens of thousands of Americans each year.

A safe, effective treatment for pain, which results in a disease burden of over $635 billion in the US alone, would have a major impact on human health through increased mobility and generally improved life quality. With N-001, we hope to accomplish this without systemic side effects like nausea, dizziness, and addiction.

Headquartered in Lincoln, Nebraska, Neurocarrus was founded by prominent research scientists in the field of protein engineering, and is led by a strong management team with expertise in business, biotechnology and medicine. Since inception, the company has generated extensive in vitro and in vivo data supporting the efficacy of N-001.

The OCMX™ is pleased to announce the listing of Neurocarrus to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Neurocarrus and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Neurocarrus exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


Paul Blum Ph.D. – Chairman

University professor endowed chair of microbiology at University of Nebraska 1990-current. Adjunct professor at University California Santa Cruz in 2017. invented the technology behind Neurocarrus. Has 25 years experience in protein engineering required for product design and production and 30 years experience as core facility manager for the pharmaceutical industry.

Key Career Milestones Achieved:

Several patents some highly successful. Over 100 papers published. Invented technology for Neurocarrus and started the company in 2017.

Founder has been working in space for 25 years. The Neurocarrus product does not have addictive potential because it stays local and doesn’t cross the blood barrier. It outcompetes opiates in terms of dosage and duration in animal efficacy trials. Blum completed IndieBio Accelerator Spring 2018 (class 6). Neurocarrus has early animal trials showing pain relief equal to that of opioids but lasting 7x as long.

Blum earned his Ph.D. from University California, Davis in 1986. Followed by Postdoctoral from University California Berkeley in 1988 and Postdoctoral from Stanford Medical School in 1990.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here